EMEA-001656-PIP02-19
Key facts
Active substance |
Momelotinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0249/2019
|
PIP number |
EMEA-001656-PIP02-19
|
Pharmaceutical form(s) |
Film-coated tablet
|
Condition(s) / indication(s) |
Treatment of myelofibrosis
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
GlaxoSmithKline Trading Services Limited
Tel. +1 438-899-8201 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|